Genetic Discoveries Link to the Most Common Pediatric Bone Cancer

Recent research conducted at Cleveland Clinic Children's has uncovered a previously unknown genetic factor associated with osteosarcoma, the leading malignant bone tumor seen in children and young adults. The study, published in the Journal of Clinical Oncology, analyzed the genetic data of nearly 6,000 pediatric cancer patients and compared it to over 14,000 adults without cancer. Using advanced databases and prediction tools, the research focused on 189 genes involved in DNA repair pathways. Results revealed that some children inherit mutations in specific DNA repair genes that potentially elevate their risk of developing certain cancers.

A notable gene, SMARCAL1, was identified as a significant risk factor for osteosarcoma. About 2.6% of children with this cancer carry inherited mutations in SMARCAL1, which may impair DNA repair mechanisms and promote tumor development. Dr. Richa Sharma, the senior author, emphasized that these findings enhance our understanding of osteosarcoma's biology, enabling earlier detection and paving the way for targeted treatments. Considering the limited progress in osteosarcoma therapies over the last four decades, this discovery holds promise for transforming patient care.

Osteosarcoma primarily develops in the bones of the arms or legs and manifests through symptoms like persistent bone pain, lumps, swelling, and increased fracture risk. Annually, fewer than 1,000 cases are reported in the U.S., with survival rates improving if the disease remains localized—approximately 70% survival—versus a 20% survival rate if it spreads. This study was a collaborative effort involving institutions such as St. Jude's Children's Research Hospital, Mayo Clinic, and Kitz Hopp Children's Cancer Center in Heidelberg, Germany.

For more detailed insights, the study can be accessed via the DOI: 10.1200/JCO-25-01114.